Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05869669 · ClinicalTrials.gov registry record · Phase 2
RewinD-LB - Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies
A Phase 2 study of Dementia With Lewy Bodies, sponsored by EIP Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 159
- Enrollment target
- 20
- Study locations
NCT05869669: Completed Phase 2 study of Dementia With Lewy Bodies, sponsored by EIP Pharma.
NCT05869669 is a Phase 2 study of Dementia With Lewy Bodies that has completed, run by EIP Pharma. The registered enrollment target is 159 participants, below the 464-participant average among 22 other Dementia With Lewy Bodies trials with a reported enrollment target (66% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05869669, a Phase 2 study of Dementia With Lewy Bodies, has completed, sponsored by EIP Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 159 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine whether neflamapimod can improve learning skills, problem solving skills, and memory loss in people diagnosed with DLB. More specifically, improvement in verbal learning, memory, and attention, as well as cognitive and functional performance will be measured.
Primary Outcome
Evaluate the efficacy of neflamapimod, compared to placebo, as a treatment for DLB, as assessed by the CDR-SB scale. CDR-SB scores range from 0 to 18 with a higher score indicating worsening of cognitive impairment.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Neflamapimod
Study Locations (20)
California
- UCSD Health Sciences - Movement Disorders Center - La Jolla
- Hoag Memorial Hospital Presbyterian - Newport Beach
- Stanford Neuroscience Health Center - Palo Alto
- SC3 Research Group - Pasadena
Florida
- JEM Research Institute - Lake Worth
- ClinCloud - Melbourne
- AdventHealth Neuroscience Research - Orlando
- Panhandle Research and Medical Clinic - Pensacola
Arizona
- Barrow Neurological Institute - Phoenix
- Banner Sun Health Research Institute - Sun City
- Banner Alzheimer's Institute - Edson Family Lewy Body Dementia Center - Tucson
Colorado
- University of Colorado - Dept of Neurology - Aurora
District of Columbia
- Georgetown Univ Hospital - Dept of Neurology - Washington D.C.
Kansas
- University of Kansas Medical Center - Kansas City
Louisiana
- Tandem Clinical Research - Marrero
Maryland
- Johns Hopkins School of Medicine - Dept of Neurology - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 159 participants |
| Start Date | 2023-05-01 |
| Est. Completion | 2025-06-16 |
| Phase | Phase 2 |
What the finished NCT05869669 record still lists
NCT05869669 is an interventional study that assigns participants to a tested intervention. The registered 159 participants enrollment target is mid-sized for trials with a published cap, below the 464-participant average among 22 other Dementia With Lewy Bodies trials with a reported enrollment target (66% lower).
The record links to 1 condition, with Dementia With Lewy Bodies appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05869669 names 20 study sites across 12 states, led by California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT05869669 about?
NCT05869669 is a clinical study titled "RewinD-LB - Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies". The purpose of this study is to determine whether neflamapimod can improve learning skills, problem solving skills, and memory loss in people diagnosed with DLB. More specifically, improvement in verbal learning, memory, and attention, as well as cognitive and functional performance will be measured...
What is the current status of trial NCT05869669?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 159 participants. The study started on 2023-05-01. Estimated completion is 2025-06-16.
What conditions does trial NCT05869669 study?
This clinical trial studies the following conditions: Dementia With Lewy Bodies.
What interventions are being tested in trial NCT05869669?
The interventions under investigation include: Placebo (DRUG), Neflamapimod (DRUG).
Who is sponsoring clinical trial NCT05869669?
This trial is sponsored by EIP Pharma, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05869669 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dementia With Lewy Bodies
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05869669's enrollment target sits among peer trials
159 12th of 22 higher than 11 of 22 other Dementia With Lewy Bodies trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Dementia With Lewy Bodies trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Impact of Nilotinib on Safety, Tolerability, Pharmacokinetics and Biomarkers in Dementia With Lewy Bodies
RECRUITING · Phase 2
-
K0706 for Patients Diagnosed With Dementia With Lewy Bodies
RECRUITING · Phase 2
-
Imaging Inflammation in Patients With Parkinson's Disease Dementia or Dementia With Lewy Bodies
COMPLETED · Phase 2
-
PET Imaging Evaluation of [11C]SY08
RECRUITING · Early Phase 1
-
Elucidating the Role of Cholinergic Degeneration in Cognitive Fluctuations in Lewy Body Dementia
RECRUITING · Phase 4
-
Identification of Prodromal Neurodegeneration in Serotonergic-Induced REM Sleep Behavior Disorder
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05267626 · 159 participants · Phase 1
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
- NCT06321575 · 159 participants · NA
The Golazo® Peripheral Atherectomy System for a Safe and Effective Atherectomy (GREAT Trial)
- NCT06729151 · 159 participants
Effect of Intradetrusor onabotulinumtoxinA Injection Versus Conservative Management on Female Sexual Function in Patients With Bladder Pain Syndrome
- NCT07023731 · 159 participants · Phase 1
A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI